Neurocrine Biosciences announced today the issuance of U.S. Patent No. 6,903,106 covering a novel polymorphic form (different crystal structure) of its proprietary compound indiplon for the treatme
With a number of other non-profit groups, ITSSD is calling attention to Brazil's threat to break U.S. patents on American AIDS drugs used as part of Brazil's government-funded treatment program. After r
Cordis Corporation today announced that a U.S. District Court jury in Wilmington, Delaware found that Boston Scientific's Taxus drug-eluting stent and its Liberte and Express bare metal stents infringe
Myriad Genetics has announced the issuance of Patent No. 6,911,466 entitled, "AB42 Lowering Agents". Myriad holds exclusive rights to the patent under a licensing agreement with Mayo Clinic. The patent
In another step to decipher information in the human genome, scientists have discovered the location and sequence of over 10,000 DNA regions that function as genetic on-off switches, or "promoters" in human fibroblasts. Fibroblasts are relative
Bioheart has announced that the U.S. Patent and Trademark Office issued the company a notice of allowance regarding its patent application 09/858,046, entitled Method For Inducing Angiogenesis By
Power3 Medical Products announced today that it has converted two provisional patent applications by the filing of two utility patent applications with the United States Patent and Trademark Off
Introgen Therapeutics has announced that a patent with broad claims directed to combination therapy with the p53 gene and conventional chemotherapy or radiation was issued in China. Patent ZL95192776
Misonix, Inc. has announced today that its majority-owned Sonora Medical Systems, Inc. subsidiary has received the first of three patents filed for
BioLife Solutions announced today that it was granted a U.S. patent that covers the methods and compositions for the preservation of cells, tissues or organs in the vitreous state. Bi
This enabling technology is important for the rapid and efficient generation of genetically evolved sublines that exhibit desired phenotypes for uncovering genetic pathways associated with disease as well as discovery and product development.
Dr. Nicholas Nicolaides, President and Chief Executive Officer of Morphotek, commented, "This is yet another expansion of our intellectual property and further extends Morphotek's competitive advantage in the field of directed cell-based evolution for systems biology and product development."
"The claims in this patent are very broad and cover the genome-wide manipulation of mammalian cells to generate pools of sibs exhibiting a wide range of traits, such as sublines expressing enhanced levels of a therapeutic biologic for scaleable manufacturing as well as evolution of target cells for developing sublines suitable for drug screening and target discovery," added Dr. Philip M. Sass, Executive Vice President and Chief Operating Officer.
The mismatch repair pathway is a highly conserved process that all living organisms use to repair naturally occurring mutations that occur during DNA replication. Morphotek has developed a broad patent estate that covers regulation of this process in single celled organisms such as bacteria, yeast and mammalian cells as well as in more complex multicellular organisms such as rodents and plants. These patents also cover the use of derived organisms for the generation of a variety of commercially important traits (gene and pathway discovery, antibody maturation, vaccine development and titer optimization). Morphotek has formed successful collaborations that implement its proprietary technology for discovery and product development with Abgenix, Centocor, The Ludwig Institute for Cancer Research, The National Cancer Institute, Novo Nordisk, Protein Design Labs, Tanox, The Wistar Institute, Wyeth and the United States military.
http://www.morphotek.com/